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Abstract 
Bisphosphonate (BP) compounds are widely used in the treatment of bone disorders. This group of drugs with a high 
affinity to Ca+2 ions is rapidly attracted to bone mineral, especially in areas of high resorption. We have engineered 
unique biodegradable BP nanoparticles (NPs) by dispersion co‑polymerization of the monomers methacrylate‑PEG‑
BP) and (3‑Aminopropyl)mathacrylamide) with the crosslinker monomer tetra ethylene glycol diacrylate. These NPs 
possess a dual functionality: (1) covalent attachment of a dye (e.g. near IR dye) or a drug to the nanoparticles through 
the primary amine groups on the surface of the NPs; (2) chelation to the bone mineral hydroxyapatite through the BP 
on the surface of the NPs. This study describes the uptake of the unique near IR fluorescent Cy 7‑conjugated BP NPs 
in bone of a young mouse model. Blood half‑life studies revealed a relatively long half‑life (approximately 5 h) due to 
a high concentration of PEG in the BP NPs as well as a relatively long whole body clearance (approximately 2 weeks). 
Body distribution studies showed a specific uptake of the BP NPs in bone. These unique engineered BP NPs are 
planned to be utilized in future work for diagnostic and drug delivery systems that are targeted to bone disorders.
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Background
Bisphosphonates (BPs) are widely used in the treatment 
of bone diseases such as osteoporosis [1, 2], Paget’s dis-
ease [3, 4] and various cancers [5, 6]. This group of drugs, 
due to their high affinity to Ca+2 ions, rapidly localizes to 
bone mineral, especially in areas of high resorption [3]. 
BP bind to hydroxyapatite (HAP) either through a biden-
tate chelation or through a tridentate chelation, which 
is attributed to the two phosphonate groups and the 
hydroxyl side chain (R1) [3]. BP, as opposed to pyrophos-
phate (PPi), the endogenous analog, is resistant to hydrol-
ysis due to the presence of the P–C–P bond (Fig. 1).
At the resorption site, BPs inhibit osteoclast activ-
ity through an intracellular pathway, which is associated 
with the R2 side chain. The bioactivity of BPs can be 
described either as simple BP (non-nitrogen contain-
ing BP) or as nitrogen containing BP (N-BP). The simple 
BPs mimic PPi by metabolically integrating into non-
hydrolysable analogues of ATP. On the other hand N-BPs 
inhibit the mevalonate biosynthetic pathway [3, 7].
BPs are administered orally or intravenously [8]. Oral 
absorption of BPs is relatively poor (<1  %) whereas fol-
lowing IV administration approximately 50 % is integrated 
into the bone. BPs are eliminated via the renal system. The 
BPs taken up by the bone remain in situ for a long period, 
depending on the rate of the bone remodeling cycle, and 
are released back into the blood stream [8].
Polyethylene glycol (PEG) is a non-toxic, biocompat-
ible, non-immunogenic polymer, and is widely used 
in biopharmaceuticals to improve pharmacokinetics. 
PEGylation modifies the physical and chemical proper-
ties of the drug, and can decrease immunogenicity and 
improve drug solubility. In addition PEGylation improves 
Open Access
*Correspondence:  shlomo.margel@mail.biu.ac.il 
1 Department of Chemistry, The Institute of Nanotechnology 
and Advanced Materials, Bar‑Ilan University, 52900 Ramat Gan, Israel
Full list of author information is available at the end of the article
Page 2 of 8Rudnick‑Glick et al. J Nanobiotechnol  (2015) 13:80 
drug stability. Consequently, it extends blood half-life 
and therefore reduces dose frequency [9, 10].
In the past few years, near-infrared (NIR) fluorescent 
imaging has attracted much interest for its potential use 
in in vivo imaging applications. NIR fluorescence (700–
900 nm) exhibits low auto-fluorescence and higher pen-
etration, compared to UV and visible light, due to lower 
light scattering by the biological tissue at this wavelength 
[11, 12].
A variety of nanoparticles (NPs) containing NIR fluo-
rescent dyes have been developed, including those based 
on silica, calcium phosphate and lipoprotein [13, 14]. 
They exhibit many advantages over free NIR dye. These 
include enhanced photostability and biocompatibility. 
Due to the large surface area of the NPs many functional 
groups are available to the conjugation of a relatively 
large number of dye molecules thus leading to a signifi-
cant improvement of the fluorescent signal.
In this work we describe the use of a novel bone imag-
ing NP which utilizes BP functional groups (Fig.  1) in 
order to target areas of high resorption. In a previous 
study by our group we demonstrated that these biode-
gradable poly(ethylene glycol) BP NPs (BP NPs) possess a 
similar inhibition activity to Alendronate [10] and hence 
could be considered a suitable bone targeting agent. The 
functional cross-linked BP NPs of a narrow size distribu-
tion, with a dry diameter of 43 ±  5 nm and a hydrody-
namic diameter of 160 ± 13 nm [15], were synthesized by 
heterogeneous dispersion co-polymerization of the new 
BP monomer MA-PEG-BP (methacrylate-PEG-BP) [10] 
with the monomer APMA (3-Aminopropyl)mathacryla-
mide) and the crosslinker monomer TTEGDA (tetra eth-
ylene glycol diacrylate). The monomer APMA contains a 
primary amine which allows for the covalent binding of 
a dye to the surface of the particles. For optical imaging 
of areas of high bone resorption, the NIR dye (Cy 7) was 
covalently attached to the surface of these BP NPs [15]. In 
ovo imaging on a chicken embryo model clearly indicated 
the affinity of these BP NPs to the chicken embryo bones 
[15].
Due to BP NPs high affinity to areas of active bone 
turnover these NPs can be utilized in the diagnostics and 
therapy of a variety of bone disorders, which are charac-
terized by high exposure of calcium ions, e.g. osteoporo-
sis, primary and metastatic bone cancer, Paget’s disease. 
In this study we investigated the in  vivo imaging appli-
cation of these NIR fluorescent Cy 7-conjugated BP NPs. 
The study was carried out on a 4 week old mouse model 
which was at the stage of rapid bone development. We 
followed the body distribution and whole body clear-
ance, and evaluated the half-life of the NIR fluorescent 
Cy 7-conjugated BP NPs. In particular the BP NPs bone 
targeting ability and retention was studied.
Methods
Chemicals
The following analytical-grade chemicals were purchased 
from commercial sources and used without further 
Fig. 1 BP compared to the novel poly(ethylene) BP NP which consists of multiple BP functional groups and primary amines per particle. The free 
amine groups on the surface are available for the conjugation of a dye/drug
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purification: polyethylene glycol methacrylate (MA-PEG, 
Mn 360), tetraethylene glycol diacrylate (TTEGDA), pol-
yethylene glycol methacrylate ether (MA-PEG-OCH3, 
Mn 300), potassium persulfate (PPS), O-[(N-Succinimi-
dyl) succinyl-aminoethyl-O′-methylpolyethylene glycol 
(PEG-NHS, Mw 750), polyvinylpyrrolidone (PVP, Mw 
360  K), sodium hydroxide (NaOH, 1  N), hydrochloric 
acid (HCl, 1 N), anhydrous dichloromethane, anhydrous 
N,N-dimethylformamide (DMF), chromium oxide, iso-
propanol, magnesium sulfate (97 %), triethylamine (99 %), 
methanesulfonyl chloride, sodium chloride, sodium azide 
(99.5  %), triphenylphosphine, glycine and O,O′-Bis[2-
(N-succinimidyl-succinylamino)ethyl]polyethylene gly-
col (NHS-PEG-NHS, MW 3,000) from Sigma (Rehovot, 
Israel); N-(3-aminopropyl) methacrylamide hydrochlo-
ride, (APMA) from Polysciences, Inc. (Warrington, PA, 
USA) Dialysis membrane (1000 K–16 MM), bicarbonate 
buffer (BB, 0.1 M, pH 8.4), sodium carbonate and sodium 
bicarbonate (BB) from Bio-Lab Ltd. (Jerusalem, Israel); 
Cy 7-NHS ester from Lumiprobe Corporation (Florida, 
USA); Dulbecco’s phosphate-buffered saline (PBS) from 
Biological Industries (Bet Haemek, Israel). Water was 
purified by passing deionized water through an Elgastat 
Spectrum reverse osmosis system (Elga Ltd., High 
Wycombe, UK).
Synthesis of MA‑PEG‑BP
The monomer MA-PEG-BP was prepared as described 
in the literature [10]. Jones Reagent was prepared by 
adding H2SO4 (900 μL) to an ice-cooled vial containing 
CrO3 (900  mg), followed by addition of distilled water 
(2.7 mL). The orange mixture was stirred to homogene-
ity. MA-PEG-OH (1, 1.95 mL, 6 mmol) was stirred with 
dry acetone (30  mL) and cooled in an ice-bath. Jones 
Reagent (3.6 mL, 1.5 eq.) was then added dropwise. The 
mixture was stirred while cooling for 30 min and then left 
to warm to room temperature (rt) and stirred at rt over-
night. i-PrOH (2 mL) was added. The mixture was stirred 
for 1  h and then evaporated to remove acetone and 
i-PrOH. The resulting aqueous solution was extracted 
three times with chloroform. The combined organic 
phases were dried over Na2SO4, followed by evaporation 
to obtain MA-PEG carboxylic acid as a slightly yellow 
liquid.
MA-PEG carboxylic acid (DM-10, 750  mg, 2  mmol) 
was dissolved in dry dichloromethane (5  mL). DMF (1 
drop) was added as catalyst, followed by oxalyl chloride 
(340 μL, 4  mmol, 2  eq.). Gas evolution was observed, 
the mixture was stirred at rt overnight and gradually 
turned orange. The resulting mixture was evaporated 
to dryness, yielding an orange oil which was dissolved 
in THF (5  mL). Tris(trimethylsilyl)phosphite (1.34  mL, 
4  mmol, 2  eq.) was added and the mixture was stirred 
at rt for 1  h and then evaporated to dryness. Methanol 
(MeOH) (5 mL) was added stirred overnight at rt. NaOH 
in MeOH (240 mg, 6 mmol) was added to the mixture. A 
white precipitate was obtained and dried in a desiccator 
overnight.
Synthesis of the BP NPs
BP NPs were prepared as described in the literature [16]. 
MA-PEG-BP 45 mg, APMA 5 mg and TTEGDA 50 mg 
(total monomers concentration was 5 % w/v) were added 
to a vial containing 8  mg of PPS (8  % w/w) as initiator 
and 20  mg PVP 360  K (1  % w/v) as stabilizer, dissolved 
in 2 mL of 0.1 M BB. The vial containing the mixture was 
purged with N2 to exclude air and then shaken at 83  °C 
for 8  h. The BP nanoparticles obtained were washed to 
remove excess reagents by extensive dialysis cycles (cut-
off of 1000 k) with purified water.
Synthesis of the NIR fluorescent Cy7‑conjugated BP NPs
NIR fluorescent BP NPs were synthesized as describe in 
the literature [16]. NIR fluorescent BP NPs were prepared 
by a reaction of the primary amino groups on the BP NPs 
with Cy7-NHS ester. Cy7-NHS ester (2 mg) was dissolved 
in 0.5 mL of anhydrous DMSO. 250 µL of the Cy7-NHS 
ester solution was then added to 5  mL of the BP NPs 
dispersed in 0.1 M BB (2 mg/mL), and the reaction was 
stirred for 1  h at rt. Blocking of residual amine groups 
was then accomplished by adding 0.5  mg of PEG-NHS. 
The reaction was then stirred for 30 min at rt. The NIR 
fluorescent-conjugated BP nanoparticles obtained were 
washed to remove excess reagents by extensive dialysis in 
purified water (cut-off of 1000 k).
NIR fluorescent control nanoparticles possessing 
OCH3 groups instead of the BP groups were prepared 
similarly, substituting the monomer MA-PEG-BP for 
MA-PEG-OCH3.
Animal experiments
All experiments in the research were conducted under 
a protocol approved by the Institutional Animal Care 
and Use Committee at Bar-Ilan University. All mice 
were weighed prior and throughout the experiments 
(20–25 g).
NIR fluorescent Cy7‑conjugated BP NPs bone targeting 
and body distribution in female BALB/C mice
Bone targeting and body distribution studies were car-
ried out on a 4  week old female BALB/C mouse model 
(Harlan Laboratories, Inc. Israel). Mice were anesthetized 
by intraperitoneal injection of Ketamine (40–80  mg/kg 
body weight) and Xylazine (5–10  mg/kg body weight), 
and their fur shaved with an electric hair clipper as neces-
sary throughout the experiment. 100 µL Cy 7-conjugated 
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BP NPs and control NPs (0.1 mg/ml) suspended in PBS 
were IV injected via the tail vein. Mice treated with PBS 
were used as a negative control group for assessment of 
tissue autofluorescence and background signals. Whole 
body, bone, blood, kidney, liver, spleen, brain and heart 
images were studied by the Maestro II in  vivo imag-
ing system, for 2D planar fluorescence imaging of small 
animals (Cambridge Research and Instrumentation, 
Inc., Woburn, MA, USA). A NIR excitation/emission fil-
ter set was used for our experiments (λex: 710–760  nm, 
λem  >  750  nm). The liquid crystal tunable filter (LCTF) 
was programmed to acquire image cubes from λ = 790–
860  nm with an increment of 10  nm per image. Tissue 
autofluorescence and undesired background signals were 
removed by spectral analysis and linear unmixing algo-
rithm. Fluorescence intensity measurements were per-
formed using ImageJ software.
Results and discussion
BP NPs synthesis and characterization
The non-toxic biodegradable functional cross-linked 
polymeric BP NPs were synthesized by heterogeneous 
dispersion co-polymerization of the new BP monomer 
MA-PEG-BP (which provides the targeting functional 
group) with the monomer APMA (containing a primary 
amine which allows for the covalent binding of a dye to 
the surface) and the crosslinker monomer TTEGDA. 
These NPs are biodegradable due to the presence of ester 
and amide bonds which can be enzymatically cleaved. As 
both MA-PEG-BP and TTEGDA contain a PEG com-
ponent it can be postulated that the NPs possess a rela-
tively long half-life [9]. These BP NPs have a dry diameter 
of 43  ±  5  nm, as analyzed using electron microscopy 
(TEM) and a hydrodynamic diameter of 160  ±  13  nm 
as measured by DLS, which concurred with previously 
published measurements [15]. The mole ratio between 
BP (belonging to the MA-PEG-BP monomer) and the 
amine groups (belonging to the APMA monomer) in 
the particle was analyzed by elemental analysis (Perkin-
Elmer 2400 series II Analyzer). The initial mole ratio of 
[MA-PEG-BP]:[APMA] prior to polymerization was 4:1, 
however after polymerization the ratio was found to be 
2.8:1. The reduction in the amount of the MA-PEG-BP 
monomer polymerized could be due to the steric effect of 
the charge on the BP monomer [16]. The NIR fluorescent 
dye Cy 7 was covalently attached to the surface of these 
BP NPs via the primary amine groups for in vivo imaging 
of the body distribution, clearance and bone affinity of 
the BP NPs. Since the initial concentration of Cy7-NHS 
was much higher than that of the –NH2 surface concen-
tration, we assume that all the surface available primary 
amine groups interacted with Cy7-NHS, so that the sur-
face mole ratio of BP to Cy7 is 2.8:1. DLS measurements 
of Cy7-conjugated BP NPs exhibited a similar hydrody-
namic diameter to the non-conjugated BP NPs.
Whole body clearance of IV injected Cy7‑conjugated BP 
NPs in a young mouse model
Increased bone resorption is characteristic of a variety of 
bone disorders, including Paget’s disease, osteoporosis, 
and primary and secondary bone cancer. Bone remod-
eling involves both resorption and formation [17]. In 
this study, 4 week old female BALB/C mice were used to 
demonstrate active bone resorption, as mice at this age 
exhibit rapid skeletal development [18].
The whole body clearance was investigated at two dif-
ferent concentrations of the Cy7-conjugated BP NPs. 
Cy7-conjugated BP NPs suspended in PBS (0.1 and 1 mg/
mL) were IV injected (100 µL) via the tail vein and were 
scanned once a week for 22 weeks (n = 10 mice per sub 
group). Fur was removed at each imaging point to pre-
vent the signal being obscured. The whole body fluo-
rescence was exposed for 1000  ms using the Maestro 
II in  vivo imaging system and fluorescence intensity 
measurements of the whole body were performed using 
ImageJ software. The spectrally unmixed, high contrast 
whole body image, 1  week post injection (Fig.  2), was 
found to be similar to initial scanned body image imme-
diately following injection, illustrating the retention of 
a high concentration of the Cy7-conjugated BP NPs. 
At 2 weeks post injection, there was a marked decrease 
in the whole body fluorescence (79 and 72  % decrease 
respectively), demonstrating a significant clearance of 
the NPs. Fluorescence continued to slowly decrease and 
at 4 weeks post injection a 91 and 80 % decrease respec-
tively was measured and appeared to be predominantly 
concentrated in the hepatic region, as well as in the legs. 
This possibly indicates the incorporation of the BP NPs 
into the structure of the developing bone which would 
eventually be released during the natural course of bone 
remodeling [3, 8]. After 22  weeks 99.5  % decrease was 
observed at both concentrations of Cy7-conjugated BP 
NPs.
Blood half‑life of Cy7‑conjugated BP NPs
Most BPs have a half-life of around 1–2 h and are elimi-
nated rapidly from the plasma in both animals and 
humans [1]. NPs also exhibit a relatively short half-
life which is dependent on particle size [19]. Fang et  al. 
demonstrated that the blood clearance of the small 
PEGylated NPs (<100  nm) was slower than that of 
larger NPs (~200  nm) with a similar formulation [20]. 
In order to determine the PEG containing BP NPs half-
life, 100  µL Cy7-conjugated BP NPs at concentrations 
of 0.1 and 1  mg/ml were IV injected via the tail vein 
of 4  week old female BALB/C mice (n =  6). Blood was 
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drawn at 0, 20  min, 1, 4, 7, 24 and 48  h post injection. 
The blood half-life of the Cy7-conjugated BP NPs was 
calculated according to a linear trend line based on the 
first 7 h post injection (Fig. 3). The coefficient used was 
y = −10.655 + 111.54 with a R2 value 0.9845, indicating 
a very good correlation. Blood half-life was found to be 
approximately 5 h. This is a relatively long half-life both 
for BPs [1] and NPs [21] and can be attributed to the high 
concentration of PEG [21–23] in the BP NPs.
Soft organ body distribution of Cy7‑conjugated BP NPs
The reduction in the NIR fluorescence signal of the whole 
body image was then further studied. A comparison was 
made between mice injected with Cy7-conjugated BP 
NPs at a concentration of 0.1 mg/mL and mice injected 
with a similar concentration of control NPs, which did 
not contain the BP functional groups. Mice (n = 9) were 
sacrificed after 4  h, 24  h and 7  days post IV injection. 
Several organs were extracted and their fluorescence 
measured using the Maestro II in  vivo imaging system 
and fluorescence intensity measurements of the individ-
ual organs were performed using ImageJ software. The 
uptake of the fluorescence differed greatly between liver 
and other extracted organs and therefore exposure times 
were adjusted accordingly. For liver, exposure time was 
5000 ms and for the rest of the organs, 10,000 ms. Hence 
the results obtained compare the rate of clearance of both 
the BP and control NPs by the individual organs and not 
a comparison of the uptake by the liver of the BP and 
control NPs, to the other organs. Whilst the liver, kidney, 
heart, lungs and spleen clearance of the Cy7-conjugated 
BP NPs in general showed a similar trend to the control 
NPs, there were some discernable differences. All organs 
showed an initial uptake after 4 h followed by a decrease 
in fluorescence after 1  day and a further decrease after 
7 days post injection (Fig. 4). No fluorescence was seen in 
the brains extracted hence may indicate that the BP NPs 
do not cross the blood brain barrier.
The liver exhibited a higher fluorescent intensity at 
lower exposure time after injection for both the BP NPs 
and the control NPs compared to the other extracted 
organs. This could be explained by the PEGylation, which 
increases NPs stability, and consequently necessitates 
hepatic degradation and excretion via the liver, into bile 
and feces. Uptake of NPs by the liver may be rapid but 
the degradation and biliary excretion is slow [24, 25]. The 
slow biliary excretion could also explain the fluorescence 
in the colon which did not decrease. On the other hand, 
the kidney fluorescence could be explained by the enzy-
matic cleavage of amide and ester bonds, which release 
the Cy7, or by break down of the NPs. The free Cy7 (or 
Fig. 2 Whole body clearance of the NIR fluorescent Cy7‑conjugated BP NPs. 100 µL of 0.1 mg/mL of cy7‑conjugated BP NP were injected via the 
tail vein, and the mice were exposed for 1000 ms (λex: 710–760 nm, λem > 750 nm) using the Maestro in vivo imaging system. Spectrally unmixed, 
high contrast whole body images were obtained after t = 0 (a), t = 1 week (b), t = 2 weeks (c) and t = 4 weeks (d). Schematic whole body fluores‑
cent clearance (e)
Fig. 3 Blood half‑life of Cy 7‑conjugated BP NPs. 100 µL of Cy7‑con‑
jugated BP NP (1 mg/mL) were IV injected via the tail vein and blood 
was drawn at different time intervals (n = 6). Insert shows the linear 
fit y = −10.655 + 111.54 with a R2 value 0.9845 for the blood half‑life
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degraded fragments of the NPs with Cy7 still attached) 
are small molecules and can be excreted by the kidney.
Bone targeting of Cy7‑conjugated BP NPs
When comparing the fluorescence of Cy7-conjugated 
BP and control NPs in bone, there is a marked differ-
ence in the findings (Fig. 5). 4 h post injection, both NPs 
exhibit a similar fluorescent intensity. However, 24 h post 
injection, the fluorescence intensity of bone treated with 
BP NPs exhibited a marked increase, whereas the fluo-
rescence of bone treated with the control NPs remained 
unchanged. 7 days post injection, the BP NPs remain at 
a high concentration in the bones and may indicate their 
incorporation into the newly formed bone.
Bone growth is associated with an enhanced blood sup-
ply to the area and the accompanying bone remodeling 
Fig. 4 Body distribution of Cy7‑conjugated BP NPs compared to control NPs. Mice were injected with 100 µL of 0.1 mg/mL of NPs, were sacrificed 
4 h, 1 and 7 days post injection and organs were harvested. Liver (a), Kidney (b), Intestine (c), Colon (d) and Heart (e). Spectrally unmixed, high con‑
trast organ images were obtained and fluorescence intensity measurements of the individual organs was performed using ImageJ software
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involves exposure of HAP, factors which lead to an accu-
mulation of BP [1, 26]. Our NIR fluorescent images 
demonstrate that the fluorescence is concentrated at the 
end of the bones, the main areas of active bone growth. 
Hence we may conclude that due to the high concentra-
tion of BP in the NPs, bone in a state of active turnover 
is preferentially targeted by the Cy 7-conjugated BP NPs.
Conclusions
In this research we investigated the uptake of Cy 7-conju-
gated BP NPs in bone in a young mouse model.
The whole body clearance of the Cy 7-conjugated BP 
NPs was followed and it was found that after 2  weeks 
the BP NPs where present at a very low concentration. 
The blood half-life of the Cy 7-conjugated BP NPs was 
calculated at approximately 5  h, which is a relatively 
long half-life for both BP and control NPs [1, 21]. This 
is attributed to the incorporation of PEG in the BP NPs. 
These results are consistent with previous studies that 
indicated PEGylated NPs (<100 nm) have a relatively long 
blood half-life and an enhanced permeability and reten-
tion (EPR) effect, hence showing the importance NPs size 
and surface composition in achieving effective, targeted 
delivery [19].
On reviewing the results of soft organ uptake, in com-
paring the clearance of Cy 7-conjugated BP NPs with 
the control NPs, no significant differences were detected 
between the harvested organs. The highest concentration 
of both NPs was found in the liver. In addition, high con-
centrations were also found in the kidneys and colon. The 
high colonic concentration may be associated with biliary 
excretion of the NPs into the GI tract [24, 25], and their 
elimination via feces, hence, the continuous fluorescence 
of the colon. On the other hand, the kidney fluorescence 
could be explained by the metabolism of the Cy 7-conju-
gated NPs, resulting in the cleavage of the amide bond. 
The free Cy7 is a small molecule and can therefore be 
excreted by the kidney.
However, bone differed from the other harvested 
organs. In bone the Cy 7-conjugated BP NPs did not 
decrease over time. The accumulated Cy 7-conjugated 
BP NPs exhibited a high and stable fluorescent concen-
tration due to the high affinity of BP to exposed HAP in 
developing bone.
This mouse model, whilst confirming previous find-
ings has limited application for the long term study of the 
targeting of BP NPs to bone resorption sites. The age of 
the mice at the start of experiment and the length of the 
rapid growth period restricts the time available for study 
[27]. Poly(MA-PEG-BP) NPs prolonged half-life and 
preferential uptake in areas of high bone activity provide 
exciting potential for these NPs to be utilized in diagnos-
tic and drug delivery systems that are targeted to bone. 
Future plans include further investigation of the bone 
targeting ability of these BP NPs on more suitable mouse 
models, such as osteoporosis and osteosarcoma models, 
and to explore their potential as a drug delivery system in 
different bone disorders.
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